The importance of total cardiovascular risk assessment in clinical practice

References

• De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2003; 10: S1–10
   PubMed Web of Science ®Google Scholar
• Dawber TR, Kannel WB, Revotskie N, Kagan A. The epidemiology of coronary heart disease—the Framingham enquiry. Proc R Soc Med 1962; 55: 265–71
   PubMedGoogle Scholar
• Greenland P, Knoll MD, Stamler J, Neaton JD, Dyer AR, Garside DB, et al. Major risk factors as antecedents of fatal and nonfatal coronary heart disease. JAMA 2003; 290: 891–7
   PubMed Web of Science ®Google Scholar
• Khot UN, Khot MB, Bayzer CT, Sapp SK, Ohman EM, Brener SJ, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003; 290: 898–904
   PubMed Web of Science ®Google Scholar
• Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987–1003
   PubMed Web of Science ®Google Scholar
• Kannel WB, Wilson PW. An update on coronary risk factors. Med Clin North Am 1995; 79: 951–71
   PubMed Web of Science ®Google Scholar
• Cucherat M, Bonnefoy E, Tremeau G. Primary angioplasty versus intravenous thrombolysis for acute myocardial infarction (Cochrane Review). The Cochrane Library 2004; Issue I. John Wiley & Sons Ltd, ChichesterUK 2004
   Google Scholar
• Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003; 361: 13–20
   PubMed Web of Science ®Google Scholar
• Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specified relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903–13
   PubMed Web of Science ®Google Scholar
• Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615–22
   PubMed Web of Science ®Google Scholar
• Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301–7
   PubMed Web of Science ®Google Scholar
• Lindstrom J, Eriksson JG, Valle TT, Aunola S, Cepaitis Z, Hakumaki M, et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish diabetes mellitus prevention study: results from a randomized clinical trial. J Am Soc Nephrol 2003; 14(Suppl 2)S108–13
   PubMedGoogle Scholar
• The Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care 2002; 25: 2165–71
   PubMed Web of Science ®Google Scholar
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–9.
   PubMed Web of Science ®Google Scholar
• Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339:1349–57.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Sacks FM, Moye LA, Brown L, Rouleau JL, Hartley LH, et al. Cholesterol and recurrent events: a secondary prevention trial for normolipidemic patients. CARE Investigators. Am J Cardiol 1995; 76: 98C–106C
   Web of Science ®Google Scholar
• Mulcahy R, Hickey N, Graham I, McKenzie G. Factors influencing long-term prognosis in male patients surviving a first coronary attack. Br Heart J 1975; 37: 158–65
   Google Scholar
• Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, et al. Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827–38
   PubMed Web of Science ®Google Scholar
• Kannel WB, McGee DL, Helbert P, Fiebach NH, Ebeilrleinte A. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care 1979; 2: 120–6
   PubMedGoogle Scholar
• De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003; 24: 1601–10
   PubMed Web of Science ®Google Scholar
• Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837–47
   PubMed Web of Science ®Google Scholar
• Joint British recommendations on prevention of coronary heart disease in clinical practice. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association. Heart 1998;80(Suppl 2):S1–29.
   PubMedGoogle Scholar
• New Zealand Guidelines Group. Guidelines for the management of mildly raised blood pressure in New Zealand. 1995. Available from URL:, , http://www.nzgg.org.nz/library/gl_complete/bloodpressure/index.htm#contents.
   Google Scholar
• World Health Organization. The world health report 2003—shaping the future. World Health Organization, Geneva 2003
   Google Scholar
• Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 2001;357:995–1001.
   PubMed Web of Science ®Google Scholar
• Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001;22:554–72.
   PubMed Web of Science ®Google Scholar
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7–22.
   PubMed Web of Science ®Google Scholar
• Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149–58
   PubMed Web of Science ®Google Scholar
• National Heart, Lung, and Blood Institute. The Framingham Heart Study. URL:, , http://www.framingham.com/heart.
   Google Scholar
• National Heart, Lung, and Blood Institute. Information for researchers. The Framingham Heart Study. Available at URL:, , http://www.nhlbi.nih.gov/about/framingham/.
   Google Scholar
• Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486–97.
   PubMed Web of Science ®Google Scholar
• Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837–47
   PubMed Web of Science ®Google Scholar
• Haq IU, Ramsay LE, Yeo WW, Jackson PR, Wallis EJ. Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk men. Heart 1999; 81: 40–6
   PubMed Web of Science ®Google Scholar
• D'Agostino RB Sr, Grundy S, Sullivan LM, Wilson P. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001; 286: 180–7
   PubMed Web of Science ®Google Scholar
• Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, et al. The Cardiovascular Health Study: design and rationale. Ann Epidemiol 1991; 1: 263–76
   PubMedGoogle Scholar
• Garcia-Palmieri MR, Costas R, Jr, Cruz-Vidal M, Cortes-Alicea M, Patterne D, Rojas-Franco L, et al. Urban–rural differences in coronary heart disease in a low incidence area. The Puerto Rico heart study. Am J Epidemiol 1978; 107: 206–15
   PubMed Web of Science ®Google Scholar
• Stern MP. Honolulu Heart Study: review of epidemiologic data and design. Prog Clin Biol Res 1984; 147: 93–104
   Google Scholar
• Lee ET, Welty TK, Fabsitz R, Cowan LD, Le NA, Oopik AJ, et al. The Strong Heart Study. A study of cardiovascular disease in American Indians: design and methods. Am J Epidemiol 1990; 132: 1141–55
   PubMed Web of Science ®Google Scholar
• The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. Am J Epidemiol 1989;129:687–702.
   PubMed Web of Science ®Google Scholar
• Menotti A, Puddu PE, Lanti M. Comparison of the Framingham risk function-based coronary chart with risk function from an Italian population study. Eur Heart J 2000; 21: 365–70
   PubMed Web of Science ®Google Scholar
• Thomsen TF, McGee D, Davidsen M, Jorgensen T. A cross-validation of risk-scores for coronary heart disease mortality based on data from the Glostrup Population Studies and Framingham Heart Study. Int J Epidemiol 2002; 31: 817–22
   PubMed Web of Science ®Google Scholar
• Hense HW, Schulte H, Lowel H, Assmann G, Keil U. Framingham risk function overestimates risk of coronary heart disease in men and women from Germany—results from the MONICA Augsburg and the PROCAM cohorts. Eur Heart J 2003; 24: 937–45
   PubMed Web of Science ®Google Scholar
• Folsom AR, Aleksic N, Park E, Salomaa V, Juneja H, Wu KK. Prospective study of fibrinolytic factors and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol 2001; 21: 611–7
   PubMed Web of Science ®Google Scholar
• Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002;288:2015–22.
   PubMed Web of Science ®Google Scholar
• Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997; 277: 1775–81
   PubMed Web of Science ®Google Scholar
• Levenson J, Giral P, Razavian M, Gariepy J, Simon A. Fibrinogen and silent atherosclerosis in subjects with cardiovascular risk factors. Arterioscler Thromb Vasc Biol 1995; 15: 1263–8
   PubMedGoogle Scholar
• Ernst E, Resch KL. Therapeutic interventions to lower plasma fibrinogen concentration. Eur Heart J 1995; 16(Suppl A)47–52
   PubMedGoogle Scholar
• Hwang SJ, Ballantyne CM, Sharrett AR, Smith LC, Davis CE, Gotto AM, Jr, et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation 1997; 96: 4219–25
   PubMed Web of Science ®Google Scholar
• Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998; 351: 88–92
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344: 1959–65
   PubMed Web of Science ®Google Scholar